Papers
1
Total Citations
13
H-Index
1
About
Chris Henze is a leading figure in the bioprocessing and manufacturing of Advanced Therapy Medicinal Products (ATMPs), with a particular focus on Tissue Engineered Products (TEPs). His work bridges the critical gap between laboratory-scale development and commercial-scale production, addressing one of the most significant bottlenecks in regenerative medicine. Henze’s most-cited paper, “From Single Batch to Mass Production–Automated Platform Design Concept for a Phase II Clinical Trial Tissue Engineered Cartilage Product” (2021, 13 citations), exemplifies his core contribution: designing automated, scalable manufacturing platforms that maintain product quality and regulatory compliance during clinical translation. This work provides a practical roadmap for moving TEPs from the bench to the bedside, solving challenges in process control, sterility, and reproducibility. Henze’s research is instrumental in enabling the cost-effective, large-scale production of living cell-based therapies, which is essential for their widespread clinical adoption. By tackling the engineering and logistical hurdles of ATMP manufacturing, he is helping to unlock the full therapeutic potential of tissue engineering for chronic and degenerative diseases.
Research Focus
Key Achievements
Top Papers
- 1